All Stories

  1. Filamentous fungus-produced human monoclonal antibody provides protection against SARS-CoV-2 in hamster and non-human primate models
  2. A pan-orthohantavirus preclinical human lung xenograft mouse model
  3. Presence of procoagulant peripheral blood mononuclear cells in severe COVID-19 patients relate to ventilation perfusion mismatch and precede pulmonary embolism
  4. Human metapneumovirus infection of organoid-derived human bronchial epithelium represents cell tropism and cytopathology as observed in in vivo models
  5. Human conjunctiva organoids to study ocular surface homeostasis and disease
  6. Direct comparison of SARS-CoV-2 variant specific neutralizing antibodies in human and hamster sera
  7. Transient Autoreactive PF4 and Antiphospholipid Antibodies in COVID-19 Vaccine Recipients
  8. Fangchinoline inhibits SARS-CoV-2 and MERS-CoV entry
  9. Comparative Pathogenesis of Severe Acute Respiratory Syndrome Coronaviruses
  10. Antigenic evolution of SARS coronavirus 2
  11. The impact of BNT162b2 mRNA vaccine on adaptive and innate immune responses
  12. Comparative Analysis of SARS-CoV-2 Antigenicity across Assays and in Human and Animal Model Sera
  13. SARS-CoV-2 ORF8 accessory protein is a virulence factor
  14. Distinct COVID-19 vaccine combinations result in divergent immune responses
  15. Glycosylated extracellular mucin domains protect against SARS-CoV-2 infection at the respiratory surface
  16. SARS-CoV-2 Omicron entry is type II transmembrane serine protease-mediated in human airway and intestinal organoid models
  17. Filamentous Fungus-Produced Human Monoclonal Antibody Provides SARS-CoV-2 Protection in Hamster and Non-Human Primate Models
  18. Preclinical immunogenicity and protective efficacy of a SARS-CoV-2 RBD-based vaccine produced with the thermophilic filamentous fungal expression system Thermothelomyces heterothallica C1
  19. Correction for Mols et al., “Intestinal Tropism of a Betacoronavirus ( Merbecovirus ) in Nathusius’s Pipistrelle Bat (Pipistrellus nathusii), Its Natural Host”
  20. Detection of double-stranded RNA intermediates of four major SARS-CoV-2 variants in formalin-fixed paraffin-embedded lung tissue of Syrian golden hamsters using monoclonal antibodies
  21. SARS-CoV-2 (B1.1.529) Omicron variant: what has changed in the nose?
  22. ICTV Virus Taxonomy Profile: Coronaviridae 2023
  23. The pro-inflammatory response to influenza A virus infection is fueled by endothelial cells
  24. Mpox Virus Impact on Kidney Organoids and Antiviral Treatment Response
  25. Preclinical immunogenicity and protective efficacy of a SARS-CoV-2 RBD based vaccine produced with the thermophilic filamentous fungal expression system Thermothelomyces heterothallica, C1.
  26. Extended Viral Shedding of MERS-CoV Clade B Virus in Llamas Compared with African Clade C Strain
  27. Intestinal Tropism of a Betacoronavirus ( Merbecovirus ) in Nathusius’s Pipistrelle Bat ( Pipistrellus nathusii ), Its Natural Host
  28. Brief Report: Monkeypox Virus Cross-Neutralizing Antibodies in Clinical Trial Subjects Vaccinated with Modified Vaccinia Virus Ankara Encoding MERS-Coronavirus Spike Protein
  29. Avidity engineering of human heavy-chain-only antibodies mitigates neutralization resistance of SARS-CoV-2 variants
  30. Reduced Seasonal Coronavirus Antibody Responses in Children Following COVID-19 Mitigation Measures, The Netherlands
  31. Antigenic mapping of emerging SARS-CoV-2 omicron variants BM.1.1.1, BQ.1.1, and XBB.1
  32. Low levels of monkeypox virus neutralizing antibodies after MVA-BN vaccination in healthy individuals
  33. Low levels of monkeypox virus neutralizing antibodies after MVA-BN vaccination in healthy individuals
  34. The pro-inflammatory response to influenza A virus infection is fueled by endothelial cells
  35. Outpatient convalescent plasma therapy for high-risk patients with early COVID-19. A randomized placebo-controlled trial
  36. Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome
  37. Pulmonary lesions following inoculation with the SARS-CoV-2 Omicron BA.1 (B.1.1.529) variant in Syrian golden hamsters
  38. Recapitulating infection, thermal sensitivity and antiviral treatment of seasonal coronaviruses in human airway organoids
  39. Persistence of MERS-CoV-spike-specific B cells and antibodies after late third immunization with the MVA-MERS-S vaccine
  40. Protective efficacy of an RBD-based Middle East respiratory syndrome coronavirus (MERS-CoV) particle vaccine in llamas
  41. Antigenic cartography of SARS-CoV-2 reveals that Omicron BA.1 and BA.2 are antigenically distinct
  42. SARS-CoV-2 Omicron variant causes mild pathology in the upper and lower respiratory tract of hamsters
  43. Potency of Fusion-Inhibitory Lipopeptides against SARS-CoV-2 Variants of Concern
  44. An early warning system for emerging SARS-CoV-2 variants
  45. An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants of concern
  46. Methods for fighting emerging pathogens
  47. Defining the risk of SARS-CoV-2 variants on immune protection
  48. SARS-CoV-2 pathogenesis
  49. Pulmonary lesions following inoculation with the SARS-CoV-2 Omicron BA.1 (B.1.1.529) variant in Syrian golden hamsters
  50. The glycosylated extracellular domain of MUC1 protects against SARS-CoV-2 infection at the respiratory surface
  51. Distinct spatial arrangements of ACE2 and TMPRSS2 expression in Syrian hamster lung lobes dictates SARS-CoV-2 infection patterns
  52. Spreading of SARS-CoV-2 from hamsters to humans
  53. Omicron BA.1 and BA.2 are antigenically distinct SARS-CoV-2 variants
  54. An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants
  55. Increased neutralization and IgG epitope identification after MVA-MERS-S booster vaccination against Middle East respiratory syndrome
  56. Modeling Infection and Tropism of Human Parainfluenza Virus Type 3 in Ferrets
  57. Divergent SARS CoV-2 Omicron-reactive T- and B cell responses in COVID-19 vaccine recipients
  58. SARS-CoV-2 Omicron variant causes mild pathology in the upper and lower respiratory tract of Syrian golden hamsters (Mesocricetus auratus)
  59. SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination
  60. SARS-CoV-2 Omicron efficiently infects human airway, but not alveolar epithelium
  61. Middle East respiratory syndrome coronavirus infection in camelids
  62. Divergent SARS CoV-2 Omicron-specific T- and B-cell responses in COVID-19 vaccine recipients
  63. Experimental and field investigations of exposure, replication and transmission of SARS-CoV-2 in pigs in the Netherlands
  64. Interferon-α2 Auto-antibodies in Convalescent Plasma Therapy for COVID-19
  65. Targeted proteomics as a tool to detect SARS-CoV-2 proteins in clinical specimens
  66. Zoonoses Anticipation and Preparedness Initiative, stakeholders conference, February 4 & 5, 2021
  67. The glycosylated extracellular domain of MUC1 protects against SARS-CoV-2 infection at the respiratory surface
  68. Author Correction: The next phase of SARS-CoV-2 surveillance: real-time molecular epidemiology
  69. A CRISPR/Cas9 genetically engineered organoid biobank reveals essential host factors for coronaviruses
  70. The next phase of SARS-CoV-2 surveillance: real-time molecular epidemiology
  71. Seasonal coronavirus-specific B-cells with limited SARS-CoV-2 cross-reactivity dominate the IgG response in severe COVID-19 patients
  72. The Post-Acute Phase of SARS-CoV-2 Infection in Two Macaque Species Is Associated with Signs of Ongoing Virus Replication and Pathology in Pulmonary and Extrapulmonary Tissues
  73. Virological characteristics of SARS-CoV-2 vaccine breakthrough infections in health care workers
  74. Evaluation of a multi-species SARS-CoV-2 surrogate virus neutralization test
  75. Interferon-α Auto-Antibodies in Convalescent Plasma Therapy for COVID-19
  76. Science, not speculation, is essential to determine how SARS-CoV-2 reached humans
  77. Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA-SARS-2-S in preclinical vaccination
  78. Animal models of SARS-CoV-2 transmission
  79. Advancing lung organoids for COVID-19 research
  80. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection
  81. SARS-CoV-2 neutralizing human antibodies protect against lower respiratory tract disease in a hamster model
  82. SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees
  83. A CRISPR/Cas9 genetically engineered organoid biobank reveals essential host factors for coronaviruses
  84. Human Respiratory Syncytial Virus Subgroup A and B Infections in Nasal, Bronchial, Small-Airway, and Organoid-Derived Respiratory Cultures
  85. Evaluation of a multi-species SARS-CoV-2 surrogate virus neutralization test
  86. The BNT162b2 mRNA vaccine against SARS-CoV-2 reprograms both adaptive and innate immune responses
  87. Human organoid systems reveal in vitro correlates of fitness for SARS-CoV-2 B.1.1.7
  88. High Levels of Neutrophil Extracellular Traps Persist in the Lower Respiratory Tract of Critically Ill Patients With Coronavirus Disease 2019
  89. Human airway cells prevent SARS-CoV-2 multibasic cleavage site cell culture adaptation
  90. Author response: Human airway cells prevent SARS-CoV-2 multibasic cleavage site cell culture adaptation
  91. A Single Subcutaneous or Intranasal Immunization with Adenovirus‐Based SARS‐CoV‐2 Vaccine Induces Robust Humoral and Cellular Immune Responses in Mice
  92. 3D visualization of SARS-CoV-2 infection and receptor distribution in Syrian hamster lung lobes display distinct spatial arrangements
  93. A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies
  94. Review for "A Single Subcutaneous or Intranasal Immunization with Adenovirus‐Based SARS‐CoV‐2 Vaccine Induces Robust Humoral and Cellular Immune Responses in Mice"
  95. Intranasal fusion inhibitory lipopeptide prevents direct-contact SARS-CoV-2 transmission in ferrets
  96. Multimerization- and glycosylation-dependent receptor binding of SARS-CoV-2 spike proteins
  97. Neutrophil extracellular traps persist at high levels in the lower respiratory tract of critically ill COVID-19 patients
  98. Human airway cells prevent SARS-CoV-2 multibasic cleavage site cell culture adaptation
  99. Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19)
  100. Immunogenicity and efficacy of the COVID-19 candidate vector vaccine MVA SARS 2 S in preclinical vaccination
  101. SARS-CoV-2 entry into human airway organoids is serine protease-mediated and facilitated by the multibasic cleavage site
  102. Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection
  103. Extended Shedding and Enhanced Fitness of the SARS-CoV-2 Variant of Concern B.1.1.7 in Human Organoid Systems
  104. The BNT162b2 mRNA Vaccine Against SARS-CoV-2 Reprograms Both Adaptive and Innate Immune Responses
  105. Susceptibility of rabbits to SARS-CoV-2
  106. Author response: SARS-CoV-2 entry into human airway organoids is serine protease-mediated and facilitated by the multibasic cleavage site
  107. Decision letter: SARS-CoV-2 entry into human airway organoids is serine protease-mediated and facilitated by the multibasic cleavage site
  108. An Organoid‐derived Bronchioalveolar Model for SARS‐CoV‐2 Infection of Human Alveolar‐type II‐like Cells
  109. Development of immunohistochemistry and in situ hybridisation for the detection of SARS-CoV and SARS-CoV-2 in formalin-fixed paraffin-embedded specimens
  110. Effects of Potent Neutralizing Antibodies from Convalescent Plasma in Patients Hospitalized for Severe SARS-CoV-2 Infection.
  111. The Importance of Biobanking for Response to Pandemics Caused by Emerging Viruses: The European Virus Archive As an Observatory of the Global Response to the Zika Virus and COVID-19 Crisis
  112. Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection
  113. Intranasal fusion inhibitory lipopeptide prevents direct contact SARS-CoV-2 transmission in ferrets
  114. Comparison of SARS-CoV-2 infection in two non-human primate species: rhesus and cynomolgus macaques
  115. How the COVID-19 pandemic highlights the necessity of animal research
  116. Isolation of cross-reactive monoclonal antibodies against divergent human coronaviruses that delineate a conserved and vulnerable site on the spike protein
  117. Severe COVID-19 patients display a back boost of seasonal coronavirus-specific antibodies
  118. Animal models for COVID-19
  119. The SARS-CoV-2 multibasic cleavage site facilitates early serine protease-mediated entry into organoid-derived human airway cells
  120. Multimerization- and glycosylation-dependent receptor binding of SARS-CoV-2 spike proteins
  121. Susceptibility of rabbits to SARS-CoV-2
  122. Homologous and heterologous antibodies to coronavirus 229E, NL63, OC43, HKU1, SARS, MERS and SARS-CoV-2 antigens in an age stratified cross-sectional serosurvey in a large tertiary hospital in The Netherlands
  123. SARS-CoV-2 neutralizing human antibodies protect against lower respiratory tract disease in a hamster model
  124. How the COVID-19 pandemic highlights the necessity of animal research
  125. Assessing the extent of SARS-CoV-2 circulation through serological studies
  126. SARS-CoV-2 is transmitted via contact and via the air between ferrets
  127. An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment
  128. Convalescent Plasma for COVID-19. A randomized clinical trial
  129. Severe Acute Respiratory Syndrome Coronavirus 2−Specific Antibody Responses in Coronavirus Disease 2019 Patients
  130. Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome
  131. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
  132. Shedding of infectious virus in hospitalized patients with coronavirus disease-2019 (COVID-19): duration and key determinants
  133. Publisher Correction: A human monoclonal antibody blocking SARS-CoV-2 infection
  134. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
  135. A human monoclonal antibody blocking SARS-CoV-2 infection
  136. Serologic Detection of Middle East Respiratory Syndrome Coronavirus Functional Antibodies
  137. SARS-CoV-2 productively infects human gut enterocytes
  138. Towards the next phase: evaluation of serological assays for diagnostics and exposure assessment.
  139. SARS-CoV-2 Productively Infects Human Gut Enterocytes
  140. Targeted Proteomics for the Detection of SARS-CoV-2 Proteins
  141. Phenotype of SARS-CoV-2-specific T-cells in COVID-19 patients with acute respiratory distress syndrome
  142. Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model
  143. SARS-CoV-2 is transmitted via contact and via the air between ferrets.
  144. Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Seropositive Camel Handlers in Kenya
  145. Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development
  146. Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial
  147. SARS-CoV-2 specific antibody responses in COVID-19 patients
  148. Comparative Pathogenesis Of COVID-19, MERS And SARS In A Non-Human Primate Model
  149. A human monoclonal antibody blocking SARS-CoV-2 infection
  150. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2
  151. Authors’ response: Plenty of coronaviruses but no SARS-CoV-2
  152. Laboratory readiness and response for novel coronavirus (2019-nCoV) in expert laboratories in 30 EU/EEA countries, January 2020
  153. Severe acute respiratory syndrome-related coronavirus: The species and its viruses – a statement of the Coronavirus Study Group
  154. Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19
  155. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR
  156. Note from the editors: novel coronavirus (2019-nCoV)
  157. Particulate multivalent presentation of the receptor binding domain induces protective immune responses against MERS-CoV
  158. Two-Component Spike Nanoparticle Vaccine Protects Macaques from SARS-CoV-2 Infection
  159. MERS-CoV in Camels but Not Camel Handlers, Sudan, 2015 and 2017
  160. Machine-learning based patient classification using Hepatitis B virus full-length genome quasispecies from Asian and European cohorts
  161. Sensitive and Specific Detection of Low-Level Antibody Responses in Mild Middle East Respiratory Syndrome Coronavirus Infections
  162. Comparison of Serologic Assays for Middle East Respiratory Syndrome Coronavirus
  163. ADAR1: “Editor-in-Chief” of Cytoplasmic Innate Immunity
  164. Failure to detect MERS‐CoV RNA in urine of naturally infected dromedary camels
  165. Species-Specific Colocalization of Middle East Respiratory Syndrome Coronavirus Attachment and Entry Receptors
  166. Lack of Middle East Respiratory Syndrome Coronavirus Transmission in Rabbits
  167. Host Determinants of MERS-CoV Transmission and Pathogenesis
  168. Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein
  169. Blocking transmission of Middle East respiratory syndrome coronavirus (MERS-CoV) in llamas by vaccination with a recombinant spike protein
  170. Co-localization of Middle East respiratory syndrome coronavirus (MERS-CoV) and dipeptidyl peptidase-4 in the respiratory tract and lymphoid tissues of pigs and llamas
  171. Chimeric camel/human heavy-chain antibodies protect against MERS-CoV infection
  172. Experimental infection of dromedaries with Middle East respiratory syndrome-Coronavirus is accompanied by massive ciliary loss and depletion of the cell surface receptor dipeptidyl peptidase 4
  173. Middle East respiratory syndrome coronavirus specific antibodies in naturally exposed Israeli llamas, alpacas and camels
  174. Multi-hospital outbreak of a Middle East respiratory syndrome coronavirus deletion variant, Jordan: A molecular, serologic, and epidemiologic investigation
  175. Tissue Distribution of the Mers-Coronavirus Receptor in Bats
  176. Cell Tropism of Middle East Respiratory Syndrome Coronavirus in Experimentally Infected Dromedaries
  177. Identification of sialic acid-binding function for the Middle East respiratory syndrome coronavirus spike glycoprotein
  178. DPP4, the Middle East Respiratory Syndrome Coronavirus Receptor, is Upregulated in Lungs of Smokers and Chronic Obstructive Pulmonary Disease Patients
  179. Phenotypic Differences between Asian and African Lineage Zika Viruses in Human Neural Progenitor Cells
  180. Identification of HCV Resistant Variants against Direct Acting Antivirals in Plasma and Liver of Treatment Naïve Patients
  181. Middle East respiratory syndrome coronavirus experimental transmission using a pig model
  182. MERS-coronavirus: From discovery to intervention
  183. Genetic diversity of hepatitis C virus in Ethiopia
  184. Tissue Distribution of the MERS-Coronavirus Receptor in Bats
  185. Virus genomes reveal factors that spread and sustained the Ebola epidemic
  186. Risk Factors for Primary Middle East Respiratory Syndrome Coronavirus Infection in Camel Workers in Qatar During 2013–2014: A Case-Control Study
  187. Middle East respiratory syndrome coronavirus vaccines: current status and novel approaches
  188. Seroepidemiology of hepatitis B and C virus infections among blood donors in Ethiopia
  189. Livestock Susceptibility to Infection with Middle East Respiratory Syndrome Coronavirus
  190. Respiratory Infection Routes of MERS-CoV in Rabbits
  191. Development of Different Animal Models for Middle East Respiratory Syndrome-Coronavirus (MERS-CoV) Infection
  192. The sample of choice for detecting Middle East respiratory syndrome coronavirus in asymptomatic dromedary camels using real-time reversetranscription polymerase chain reaction
  193. A novel hepatitis B virus subgenotype D10 circulating in Ethiopia
  194. Miscarriage Associated with Zika Virus Infection
  195. Virus genomes reveal the factors that spread and sustained the West African Ebola epidemic.
  196. Naturally occurring recombination in ferret coronaviruses revealed by complete genome characterization
  197. Toward Developing a Preventive MERS-CoV Vaccine—Report from a Workshop Organized by the Saudi Arabia Ministry of Health and the International Vaccine Institute, Riyadh, Saudi Arabia, November 14–15, 2015
  198. MERS-CoV Infection of Alpaca in a Region Where MERS-CoV is Endemic
  199. Deletion Variants of Middle East Respiratory Syndrome Coronavirus from Humans, Jordan, 2015
  200. A poxvirus-based vaccine reduces virus excretion after MERS coronavirus infection in dromedary camels
  201. Hepatitis E Virus (HEV) Genotype 3 Infection of Human Liver Chimeric Mice as a Model for Chronic HEV Infection
  202. Differential Expression of the Middle East Respiratory Syndrome Coronavirus Receptor in the Upper Respiratory Tracts of Humans and Dromedary Camels
  203. Cross host transmission in the emergence of MERS coronavirus
  204. Mers Coronavirus Infection in Dromedary Camels
  205. Ebola virus laboratory response: the three Dutch Mobile laboratories in Liberia and Sierra Leone
  206. Molecular epidemiology and genetic diversity of hepatitis B virus in Ethiopia
  207. An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels
  208. Intrathecal CD4+and CD8+T-cell responses to endogenously synthesized candidate disease-associated human autoantigens in multiple sclerosis patients
  209. Genotypic anomaly in Ebola virus strains circulating in Magazine Wharf area, Freetown, Sierra Leone, 2015
  210. Deployment of Dutch mobile laboratories in the West African Ebola virus response
  211. Follow-up of Contacts of Middle East Respiratory Syndrome Coronavirus–Infected Returning Travelers, the Netherlands, 2014
  212. Novel in vivo and in vitro models of Hepatitis E virus genotype 3 infectivity for chronic human HEV infection
  213. Occupational Exposure to Dromedaries and Risk for MERS-CoV Infection, Qatar, 2013–2014
  214. Detection of Circovirus in Foxes with Meningoencephalitis, United Kingdom, 2009–2013
  215. Asymptomatic Middle East Respiratory Syndrome Coronavirus Infection in Rabbits
  216. Reliable typing of MERS-CoV variants with a small genome fragment
  217. Inflammatory Monocytes Recruited to the Liver within 24 Hours after Virus-Induced Inflammation Resemble Kupffer Cells but Are Functionally Distinct
  218. ATP1A1-Mediated Src Signaling Inhibits Coronavirus Entry into Host Cells
  219. Genome Sequence of Enterovirus D68 and Clinical Disease, Thailand
  220. Identification of Protein Receptors for Coronaviruses by Mass Spectrometry
  221. Mers coronavirus infection of rabbits
  222. High proportion of MERS-CoV shedding dromedaries at slaughterhouse with a potential epidemiological link to human cases, Qatar 2014
  223. Pathogenesis of Middle East respiratory syndrome coronavirus
  224. Virological and serological analysis of a recent Middle East respiratory syndrome coronavirus infection case on a triple combination antiviral regimen
  225. Coronavirus Cell Entry Occurs through the Endo-/Lysosomal Pathway in a Proteolysis-Dependent Manner
  226. Travel-related MERS-CoV cases: an assessment of exposures and risk factors in a group of Dutch travellers returning from the Kingdom of Saudi Arabia, May 2014
  227. Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice
  228. Metagenomic Survey for Viruses in Western Arctic Caribou, Alaska, through Iterative Assembly of Taxonomic Units
  229. Exploring the Potential of Next-Generation Sequencing in Detection of Respiratory Viruses
  230. Geographic Distribution of MERS Coronavirus among Dromedary Camels, Africa
  231. Isolation of MERS Coronavirus from a Dromedary Camel, Qatar, 2014
  232. Novel divergent nidovirus in a python with pneumonia
  233. Geographic Distribution of MERS Coronavirus among Dromedary Camels, Africa
  234. New Viruses in Idiopathic Human Diarrhea Cases, the Netherlands
  235. The Pathology and Pathogenesis of Experimental Severe Acute Respiratory Syndrome and Influenza in Animal Models
  236. Middle East respiratory syndrome coronavirus (MERS-CoV) RNA and neutralising antibodies in milk collected according to local customs from dromedary camels, Qatar, April 2014
  237. Membrane ectopeptidases targeted by human coronaviruses
  238. Middle East respiratory syndrome coronavirus (MERS-CoV) infections in two returning travellers in the Netherlands, May 2014
  239. Neutralizing the MERS Coronavirus Threat
  240. MERS: emergence of a novel human coronavirus
  241. Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation
  242. Faculty Opinions recommendation of Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation.
  243. The Novel Human Coronavirus EMC Causes Disease in Macaques but not in Ferrets
  244. Updated Phylogenetic Analysis of Arenaviruses Detected in Boid Snakes
  245. Middle East Respiratory Syndrome coronavirus (MERS-CoV) serology in major livestock species in an affected region in Jordan, June to September 2013
  246. Adenosine Deaminase Acts as a Natural Antagonist for Dipeptidyl Peptidase 4-Mediated Entry of the Middle East Respiratory Syndrome Coronavirus
  247. Comparative efficacy, pharmacokinetic, pharmacodynamic activity, and interferon stimulated gene expression of different interferon formulations in HIV/HCV genotype-1 infected patients
  248. Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study
  249. Inhibition of Middle East Respiratory Syndrome Coronavirus Infection by Anti-CD26 Monoclonal Antibody
  250. Novel Cyclovirus in Human Cerebrospinal Fluid, Malawi, 2010–2011
  251. Middle East Respiratory Syndrome Coronavirus Spike Protein Delivered by Modified Vaccinia Virus Ankara Efficiently Induces Virus-Neutralizing Antibodies
  252. Metagenomic Analysis of the Ferret Fecal Viral Flora
  253. Spiking the MERS-coronavirus receptor
  254. Exosome-mediated transmission of hepatitis C virus between human hepatoma Huh7.5 cells
  255. Identification and Characterization of Two Novel Viruses in Ocular Infections in Reindeer
  256. The Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Does Not Replicate in Syrian Hamsters
  257. The Receptor Binding Domain of the New Middle East Respiratory Syndrome Coronavirus Maps to a 231-Residue Region in the Spike Protein That Efficiently Elicits Neutralizing Antibodies
  258. T-Cell Tropism of Simian Varicella Virus during Primary Infection
  259. MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-  treatment
  260. Identification of Multiple Novel Viruses, Including a Parvovirus and a Hepevirus, in Feces of Red Foxes
  261. Specific serology for emerging human coronaviruses by protein microarray
  262. Detection of novel divergent arenaviruses in boid snakes with inclusion body disease in The Netherlands
  263. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC
  264. Modeling Host Genetic Regulation of Influenza Pathogenesis in the Collaborative Cross
  265. Impact of Soluble CD26 on Treatment Outcome and Hepatitis C Virus-Specific T Cells in Chronic Hepatitis C Virus Genotype 1 Infection
  266. Presence of anti-interferon antibodies is not associated with non-response to peginterferon treatment in chronic hepatitis B
  267. State of Knowledge and Data Gaps of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in Humans
  268. Human Coronavirus EMC Does Not Require the SARS-Coronavirus Receptor and Maintains Broad Replicative Capability in Mammalian Cell Lines
  269. Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections
  270. Genomic Characterization of a Newly Discovered Coronavirus Associated with Acute Respiratory Distress Syndrome in Humans
  271. Performance Evaluation of the New Roche cobas AmpliPrep/cobas TaqMan HCV Test, Version 2.0, for Detection and Quantification of Hepatitis C Virus RNA
  272. Picobirnaviruses in the Human Respiratory Tract
  273. Novel Hepatitis E Virus in Ferrets, the Netherlands
  274. Calicivirus from Novel Recovirus Genogroup in Human Diarrhea, Bangladesh
  275. Impact of Obesity on the Bioavailability of Peginterferon-α2a and Ribavirin and Treatment Outcome for Chronic Hepatitis C Genotype 2 or 3
  276. Expression Quantitative Trait Loci for Extreme Host Response to Influenza A in Pre-Collaborative Cross Mice
  277. Metagenomic Analysis of the Viral Flora of Pine Marten and European Badger Feces
  278. IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C
  279. Enteric Coronavirus in Ferrets, the Netherlands
  280. Twice-weekly pegylated interferon-α-2a and ribavirin results in superior viral kinetics in HIV/hepatitis C virus co-infected patients compared to standard therapy
  281. A Recombinant Influenza A Virus Expressing Domain III of West Nile Virus Induces Protective Immune Responses against Influenza and West Nile Virus
  282. Response Prediction in Chronic Hepatitis C by Assessment of IP-10 and IL28B-Related Single Nucleotide Polymorphisms
  283. Distinct Severe Acute Respiratory Syndrome Coronavirus-Induced Acute Lung Injury Pathways in Two Different Nonhuman Primate Species
  284. Continuous interferon-α2b infusion in combination with ribavirin for chronic hepatitis C in treatment-experienced patients
  285. Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon–ribavirin combination therapy after 4 weeks of treatment
  286. Pharmacodynamics of PEG-IFN-α-2a in HIV/HCV co-infected patients: Implications for treatment outcomes
  287. 2011 IL28B POLYMORPHISM IS SIGNIFICANTLY CORRELATED WITH IFN ANTI-VIRAL EFFECTIVENESS ALREADY ON FIRST DAY OF PEGYLATED INTERFERON-α AND RIBAVIRIN THERAPY OF CHRONIC HCV INFECTION
  288. Nonresponder Patients with Hepatitis C Virus Genotype 2/3 Infection: A Question of Low Systemic Interferon Concentrations?
  289. Exacerbated Innate Host Response to SARS-CoV in Aged Non-Human Primates
  290. Therapeutic response to peg-IFN-alpha-2b and ribavirin in HIV/HCV co-infected African-American and Caucasian patients as a function of HCV viral kinetics and interferon pharmacodynamics
  291. The Application of Genomics to Emerging Zoonotic Viral Diseases
  292. Detection and biological activity of therapeutically induced antibodies to peg-IFN-α-2a in hepatitis C virus infected patients
  293. Interferon response in murine plasmacytoid dendritic cells after SARS coronavirus infection
  294. Early Upregulation of Acute Respiratory Distress Syndrome-Associated Cytokines Promotes Lethal Disease in an Aged-Mouse Model of Severe Acute Respiratory Syndrome Coronavirus Infection
  295. Early Upregulation of Acute Respiratory Distress Syndrome-Associated Cytokines Promotes Lethal Disease in an Aged-Mouse Model of Severe Acute Respiratory Syndrome Coronavirus Infection
  296. SARS
  297. Unraveling the complexities of the interferon response during SARS-CoV infection
  298. Virogenomics: the virus–host interaction revisited
  299. 27 Severe SARS coronavirus infection in aged macaques is associated with reduced expression of anti-inflammatory type-1 interferons
  300. DC-SIGN enhances infection of cells with glycosylated West Nile virus in vitro and virus replication in human dendritic cells induces production of IFN-α and TNF-α
  301. Pathology of Experimental SARS Coronavirus Infection in Cats and Ferrets
  302. Effect of postponed treatment with an anti-tumour necrosis factor (TNF) F(ab')2 fragment on endotoxin-induced cytokine and neutrophil responses in chimpanzees
  303. ALT and viral load decline during PEG-IFN alpha-2b treatment for HBeAg-positive chronic hepatitis B
  304. Complete genome analysis of hepatitis C virus subtypes 6t and 6u
  305. Severe acute respiratory syndrome (SARS) vaccines
  306. Contributors
  307. Modelling of Early Viral Kinetics and Pegylated Interferon-α2b Pharmacokinetics in Patients with HBeAg-Positive Chronic Hepatitis B
  308. HCV-Specific T-Cell Response in Relation to Viral Kinetics and Treatment Outcome (DITTO-HCV Project)
  309. Induction of Regulatory T-Cells and Interleukin-10-Producing Cells in Non-Responders to Pegylated Interferon-α Therapy for Chronic Hepatitis B
  310. Differential antiviral effect of PEG-interferon-??-2b on HIV and HCV in the treatment of HIV/HCV co-infected patients
  311. Characterization of Hepatitis C Virus Deletion Mutants Circulating in Chronically Infected Patients
  312. [520] PREDICTION OF SUSTAINED ALT NORMALIZATION BY VIRAL LOAD DURING PEG-IFN ALPHA-2b TREATMENT FOR HBeAg-POSITIVE CHRONIC HEPATITIS B
  313. P1889 Pharmacokinetic profiles in chronic hepatitis C patients treated with high-dose pegylated interferon
  314. Functional Genomics Highlights Differential Induction of Antiviral Pathways in the Lungs of SARS-CoV–Infected Macaques
  315. The emerging role of ACE2 in physiology and disease
  316. Mycophenolic Acid Inhibits Hepatitis C Virus Replication and Acts in Synergy With Cyclosporin A and Interferon-α
  317. Interferon (IFN)–γ–Inducible Protein–10: Association with Histological Results, Viral Kinetics, and Outcome during Treatment with Pegylated IFN‐α2a and Ribavirin for Chronic Hepatitis C Virus Infection
  318. Novel in-vitro and in vivo models
  319. Genotyping Hepatitis C Viruses from Southeast Asia by a Novel Line Probe Assay That Simultaneously Detects Core and 5' Untranslated Regions
  320. Interferon-γ and interleukin-4 downregulate expression of the SARS coronavirus receptor ACE2 in Vero E6 cells
  321. Coronaviruses and their therapy
  322. Identification of a Naturally Occurring Recombinant Genotype 2/6 Hepatitis C Virus
  323. Nonhuman Primate Models for SARS
  324. Antibodies Neutralizing Peginterferon Alfa during Retreatment of Hepatitis C
  325. Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: Relation to treatment response
  326. IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection
  327. Virus Specific Immune Responses after Human Neoadjuvant Adenovirus-mediated Suicide Gene Therapy for Prostate Cancer
  328. Immunisation with virion-loaded plasmacytoid or myeloid dendritic cells induces primary Th-1 immune responses
  329. Monitoring intrahepatic CD8+ T cells by fine-needle aspiration cytology in chronic hepatitis C infection
  330. Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets
  331. Host-dependent type 1 cytokine responses driven by inactivated viruses may fail to default in the absence of IL-12 or IFN- / 
  332. Pegylated interferon-α protects type 1 pneumocytes against SARS coronavirus infection in macaques
  333. 848 Neoadjuvant prostate cancer gene therapy: Clinical and pre-clinical results
  334. 494 Analysis of peripheral HCV-specific T cell responses associated with rapid viral decline during PEG-interferon-alfa-2A and ribavirin therapy (DITTO-HCV project)
  335. Pretreatment Intrahepatic CD8 + Cell Count Correlates with Virological Response to Antiviral Therapy in Chronic Hepatitis C Virus Infection
  336. SARS virus infection of cats and ferrets
  337. Prostate cancer gene therapy: Preliminary clinical and pre-clinical results
  338. Prostate cancer gene therapy: Preliminary clinical and pre-clinical results
  339. The glycosylation status of the murine hepatitis coronavirus M protein affects the interferogenic capacity of the virus in vitro and its ability to replicate in the liver but not the brain
  340. A replicon-based bioassay for the measurement of interferons in patients with chronic hepatitis C
  341. Comparative study of different methods to genotype hepatitis C virus type 6 variants
  342. Pretreatment intrahepatic CD8+ cell number correlates with virological response to antiviral therapy in chronic hepatitis C
  343. Molecular epidemiology of gibbon hepatitis B virus transmission
  344. Rat testicular germ & sertoli cells release different types of bioactive TGF-β in vitro
  345. Protective Antiviral Immune Responses to Pseudorabies Virus Induced by DNA Vaccination Using Dimethyldioctadecylammonium Bromide as an Adjuvant
  346. DITTO-HCV early viral kinetics report - novel decline patterns in gen 1 but not gen 2–3 patients treated with PEG-interferon-alfa-2a and ribavirin
  347. Long-term HBV kinetics classification during treatment with adefovir dipivoxil
  348. Identification and characterisation of adenovirus specific T cell responses in prostate cancer patients receiving ADV5-RSV-TK gene therapy
  349. Adverse effects of feline IL-12 during DNA vaccination against feline infectious peritonitis virus
  350. Corrigendum to “A DNA vaccine coding for glycoprotein B of pseudorabies virus induces cell-mediated immunity in pigs and reduces virus excretion early after infection” [Vet. Immunol. Immunopathol. 74 (2000) 121–136]
  351. Foreign-body reaction to dermal sheep collagen in interferon-?-receptor knock-out mice
  352. A DNA vaccine coding for glycoprotein B of pseudorabies virus induces cell-mediated immunity in pigs and reduces virus excretion early after infection
  353. Cytokine mRNAs in liver biopsy samples predict complete virus eradication with interferon-α ribavirin treatment in chronic hepatitis
  354. Vaccination of pigs against pseudorabies virus with plasmid DNA encoding glycoprotein D
  355. Effect of vaccination route and composition of DNA vaccine on the induction of protective immunity against pseudorabies infection in pigs
  356. Mice Lacking IL-12 Develop Polarized Th1 Cells During Viral Infection
  357. Persistence and Evolution of Feline Coronavirus in a Closed Cat-Breeding Colony
  358. Neutrophil induced T-cell apoptosis during a viral infection
  359. Neutrophil induced T-cell apoptosis during a viral infection
  360. Virus-induced type-1 cytokine response in IL-12 deficient mice
  361. Vaccination of pigs with plasmid DNA coding for glycoproteins of pseudorables virus provides protection against challenge infection with pseudorables virus
  362. Transforming growth factor beta production during rat cytomegalovirus infection.
  363. Apoptosis and T-cell depletion during feline infectious peritonitis.
  364. Tumour necrosis factor-  production during cytomegalovirus infection in immunosuppressed rats
  365. Differential effects of anti-tumor necrosis factor monoclonal antibodies on systemic inflammatory responses in experimental endotoxemia in chimpanzees
  366. Differential effects of anti-tumor necrosis factor monoclonal antibodies on systemic inflammatory responses in experimental endotoxemia in chimpanzees
  367. Suppression of rat cytomegalovirus replication by antibodies against gamma interferon.
  368. Tumor necrosis factor alpha promotes replication and pathogenicity of rat cytomegalovirus.
  369. Tumor necrosis factor α levels in cats experimentally infected with feline immunodeficiency virus: effects of immunization and feline leukemia virus infection
  370. Pneumococcal conjugate vaccines
  371. Tumour necrosis factor- , interferon-  and interferon-beta exert antiviral activity in nervous tissue cells
  372. Protection of Rats against Pseudorabies Virus Infection by  -Interferon